| Gene symbol | PCSK9 | Synonyms | FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1, PC9 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1p32.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | proprotein convertase subtilisin/kexin type 9 | ||||
| GTO ID | GTC0554 |
| Trial ID | NCT04964557 |
| Disease | Hypercholesterolemia |
| Altered gene | PCSK9 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | AZD8233|IONIS-AZ4-2.5-LRx|ION449 |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants With Hyperlipidaemia |
| Year | 2021 |
| Country | Czechia|Denmark|Hungary|Netherlands|Poland|Slovakia|Spain|United States |
| Company sponsor | AstraZeneca |
| Other ID(s) | D7990C00004|2020-005845-18 |
| Vector information | |||
|
|||
| Cohort1: AZD8233 | |||||||||
|
|||||||||
| Cohort2: Placebo | |||||||||
|
|||||||||